Often when people with asthma get a virus caused by the common cold (rhinovirus), they also
experience an increase or worsening of their asthma symptoms. The purpose of this study is to
see if the study medication dupilumab helps prevent those with mild to moderate asthma from
having increased asthma symptoms, after being exposed to an experimental rhinovirus
inoculation. This is a study about dupilumab which is a drug approved by the U.S. Food and
Drug Administration (FDA) for treatment of moderate to severe asthma. Dupilumab is a
medication that blocks pathways that cause asthmatic inflammation in the lungs, leading to
symptoms and worsening lung function. During this study, subjects will be given either
dupilumab or placebo and will subsequently be exposed to the the "common" cold virus
(rhinovirus). The virus that the investigators are using has been safely used before in many
studies like this involving thousands of volunteers, and the safe use of the virus in this
research study has been reviewed by the FDA. The investigators will track asthma symptoms
during the study with lung function tests, questionnaires, specimen collection, biomarkers,
and physical exams. For data analysis the investigators will assess the samples collected to
determine changes in the treatment groups. The investigators will also asses the symptom
scores and deviations from baseline measures for lung function.